Your AI-Trained Oncology Knowledge Connection!

Video

Selecting the Appropriate Patients With MM for Treatment With Isa-Kd

Author(s):

Brea Lipe, MD,Peter Forsberg, MD

Oncologists debate which patient populations most benefit from isatuximab plus carfilzomib and dexamethasone.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Alfred L. Garfall, MD
Joshua Richter, MD of Tisch Cancer Institute
Guenther Koehne, MD, deputy director and chief of Stem Cell Transplantation, Hematologic Oncology and Benign Hematology at Miami Cancer Institute, Baptist Health South Florida
2 experts in this video
Related Content
Bhagirathbhai Dholaria, MBBS
March 18th 2025

Off-the-Shelf CAR T-Cell Therapy P-BCMA-ALLO1 Is Efficacious in Relapsed/Refractory Multiple Myeloma

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Multiple Myeloma | Image Credit: © Свет Лана – stock.adobe.com
March 12th 2025

Anti-CD38-CAR-γδ T Cells Show Preclinical Cytotoxicity in Myeloma

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

Multiple Myeloma | Image credit: © Nittaya – stock.adobe.com
February 28th 2025

CHMP Recommends Conditional Approval of Linvoseltamab for R/R Multiple Myeloma

Rafael Fonseca, MD
February 27th 2025

The Rapid Evolution of Multiple Myeloma Treatment in Recent Years